BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:59 PM
 | 
Jul 08, 2008
 |  BC Extra  |  Clinical News

NeuroSearch gains on obesity data

NeuroSearch (CSE:NEUR) gained DKK34.5 (15%) to DKK258 on Tuesday after reporting 24-week data from the Phase II TIPO-4 trial of tesofensine to treat obesity. All 140 patients in the open-label, 48-week extension of the...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >